Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles For Members Only Hedgies Eye Three Biopharma IPOs Stephen Taub Why Top Pensions Like Verizon and Lockheed Martin are Outsourcing to Goldman James Comtois Institutional Investor enters next chapter of growth with Apax Partners Sponsored by Apax